ABSTRACT
Transdermal administration remains an active research and development area as an alternative route for long-acting drug delivery. It avoids major drawbacks of conventional oral (gastrointestinal side effects, low drug bioavailability, and need for multiple dosing) or parenteral routes (invasiveness, pain, and psychological stress and bio-hazardous waste generated from needles), thereby increasing patient appeal and compliance. This review focuses on the current state of long-acting transdermal drug delivery, including adhesive patches, microneedles, and molecularly imprinted polymeric systems. Each subsection describes an approach including key considerations in formulation development, design, and process parameters with schematics. An overview of commercially available conventional (adhesive) patches for long-acting drug delivery (longer than 24 h), the reservoir- and matrix-type systems under preclinical evaluation, as well as the advanced transdermal formulations, such as the core-shell, nanoformulations-incorporated and stimuli-responsive microneedles, and 3D-printed and molecularly imprinted polymers that are in development, is also provided. Finally, we elaborated on translational aspects, challenges in patch formulation development, and future directions for the clinical advancement of new long-acting transdermal products.
Subject(s)
Administration, Cutaneous , Delayed-Action Preparations , Drug Delivery Systems , Humans , Animals , Transdermal Patch , Needles , Pharmaceutical Preparations/administration & dosage , Pharmaceutical Preparations/chemistryABSTRACT
The DESIRE Study (MTN-035) explored product preference among three placebo rectal microbicide (RM) formulations, a rectal douche (RD), a suppository, and an insert, among 210 sexually active transgender people and men who have sex with men in five counties: the United States, Peru, Thailand, South Africa, and Malawi. Participants used each product prior to receptive anal sex (RAS) for 1 month, following a randomly assigned sequence, then selected their preferred product via computer assisted self-interview. In-depth interviews examined reasons for preference. We compared product preference and prior product use by country to explore whether geographic location and experience with the similar products impacted preference. A majority in the United States (56%) and Peru (58%) and nearly half in South Africa (48%) preferred the douche. Most in Malawi (59%) preferred the suppository, while half in Thailand (50%) and nearly half in South Africa (47%) preferred the insert. Participants who preferred the douche described it as quick and easy, already routinized, and serving a dual purpose of cleansing and protecting. Those who preferred the insert found it small, portable, discreet, with quick dissolution. Those who preferred the suppository found the size and shape acceptable and liked the added lubrication it provided. Experience with product use varied by country. Participants with RD experience were significantly more likely to prefer the douche (p = 0.03). Diversifying availability of multiple RM dosage forms can increase uptake and improve HIV prevention efforts globally.
RESUMEN: El estudio DESIRE (MTN-035) exploró la preferencia de producto entre tres formulaciones de microbicida rectal (MR) de placebo, una ducha rectal, un supositorio y un inserto, entre 210 personas transgénero y hombres que tienen sexo con hombres en cinco países: los Estados Unidos, Perú., Tailandia, Sudáfrica y Malawi. Los participantes utilizaron cada producto antes del sexo anal receptive (SAR) durante un mes, siguiendo una secuencia asignada al azar, luego seleccionaron su producto preferido mediante una autoentrevista asistida por computadora. Las entrevistas en profundidad examinaron los motivos de preferencia. Comparamos la preferencia de producto y el uso previo del producto por país para explorar si la ubicación geográfica y la experiencia con la forma farmacéutica impactaron la preferencia. Una mayoría en los Estados Unidos (56%) y Perú (58%) y casi la mitad en Sudáfrica (48%) prefirieron la ducha rectal. La mayoría en Malawi (59%) prefirió el supositorio, mientras que la mitad en Tailandia (50%) y casi la mitad en Sudáfrica (47%) prefirió el inserto. Los participantes que prefirieron la ducha rectal la describieron como rápida y fácil, ya parte de su rutina y que tenía el doble propósito de limpiar y proteger. Los que prefirieron el inserto lo consideraron pequeño, portátil, discreto y de rápida disolución. Los que prefirieron el supositorio encontraron que tenía un tamaño y forma aceptables y proveía lubricación adicional. La experiencia con el uso del producto varió según el país. Los participantes con experiencia con duchas rectales tenían significativamente más probabilidades de preferir la ducha rectal (p = 0,03). Diversificar la disponibilidad de múltiples formas farmacéuticas de MR puede aumentar la aceptación y mejorar los esfuerzos de prevención del VIH a nivel mundial.
Subject(s)
Administration, Rectal , HIV Infections , Homosexuality, Male , Sexual and Gender Minorities , Humans , Male , Thailand , HIV Infections/prevention & control , Malawi , Sexual and Gender Minorities/psychology , United States , Adult , Female , Young Adult , South Africa , Homosexuality, Male/psychology , Suppositories , Adolescent , Peru , Patient Preference , Sexual Behavior , Transgender Persons/psychology , Anti-Infective Agents/administration & dosage , Placebos/administration & dosage , Dosage FormsABSTRACT
BACKGROUND: On-demand topical products could be an important tool for HIV prevention. We evaluated the safety, pharmacokinetics, and ex vivo pharmacodynamics of a tenofovir alafenamide/elvitegravir (TAF/EVG; 16 mg/20 mg) insert administered rectally. METHODS: MTN-039 was a Phase 1, open-label, single-arm, 2-dose study. Blood, rectal fluid (RF), and rectal tissue (RT) were collected over 72 hours (hr) following rectal administration of one and two TAF/EVG inserts for each participant. ClinicalTrials.gov Identifier: NCT04047420. RESULTS: TAF/EVG inserts were safe and well tolerated. EVG and tenofovir (TFV) were detected in blood plasma at low concentrations: median peak concentrations after 2 inserts were EVG 2.4 ng/mL and TFV 4.4 ng/mL. RT EVG peaked at 2-hr (median 2 inserts= 9 ng/mg) but declined to BLQ in the majority of samples at 24-hr, whereas TFV-DP remained high >2,000 fmol/million cells for 72-hr with 2 inserts. Compared to baseline, median cumulative log10 HIV p24 antigen of ex vivo rectal tissue HIV infection was reduced at each timepoint for both 1 and 2 inserts (p<0.065 and p<0.039, respectively). DISCUSSION: Rectal administration of TAF/EVG inserts achieved high rectal tissue concentrations of EVG and TFV-DP with low systemic drug exposure and demonstrable ex vivo inhibition of HIV infection for 72 hours.
ABSTRACT
INTRODUCTION: End-user perspectives are vital to the design of new biomedical HIV prevention products. Conjoint analysis can support the integration of end-user perspectives by examining their preferences of potential pre-exposure prophylaxis (PrEP) products. The Microbicides Trial Network (MTN) 035 protocol examined three placebo rectal dosage forms (insert, enema and suppository) that could deliver PrEP prior to receptive anal sex (RAS). METHODS: Between April 2019 and July 2020, we enrolled 217 HIV-negative, cisgender men who have sex with men (MSM; n = 172; 79.3%) and transgender people (n = 47; 20.7%) ages 18-35 into a randomized cross-over trial across Malawi, Peru, South Africa, Thailand and the United States. Participants used each product prior to RAS over 4-week periods. Participants completed a conjoint experiment where they selected between random profiles using seven features (dosage form, timing of use before sex, side effects, duration of protection, effectiveness, frequency of use and need for a prescription). RESULTS: Effectiveness was the strongest determinant of choice (30.4%), followed by modality (18.0%), potential side effects (17.2%), frequency of use (10.8%), duration of protection (10.4%), timing of use before sex (7.4%) and need for a prescription (5.9%). Relative utility scores indicated that the most desirable combination of attributes was a product with 95% efficacy, used 30 minutes before sex, offering a 3- to 5-day protection window, used weekly, having no side effects, in the form of an enema and available over-the-counter. CONCLUSIONS: Choice in next-generation PrEP products is highly desired by MSM and transgender people, as no one-size-fits-all approach satisfies all the preferences. MTN-035 participants weighed product features differently, recognizing the need for diverse, behaviourally congruent biomedical options that fit the needs of intended end-users.
Subject(s)
Anti-Infective Agents , HIV Infections , Sexual and Gender Minorities , Humans , Male , Anti-Infective Agents/therapeutic use , HIV Infections/drug therapy , HIV Infections/prevention & control , Homosexuality, Male , Sexual Behavior , United States , Female , Adolescent , Young Adult , AdultABSTRACT
HIV/AIDS remains a global public health issue, and products available for the prevention of HIV infections are limited, especially those for short-acting, on-demand, user-controlled applications. Topical inserts are products that can be applied vaginally or rectally and have been explored as drug delivery systems. To fill the gap in the HIV prevention product pipeline, CONRAD has developed a topical insert containing tenofovir alafenamide fumarate (TAF) and elvitegravir (EVG), two potent and synergistic antiretrovirals, as a simple, low-cost, and discreet option that can be self-administered vaginally and/or rectally, before and after coitus. In this review, we have described the development path of the TAF/EVG insert up to its current point in clinical testing, highlighting findings from acceptability, preclinical safety, pharmacokinetics, and efficacy evaluations and early clinical studies. In summary, the TAF/EVG inserts are stable, easy to manufacture, low-cost, acceptable, and show highly promising preclinical and clinical results for on-demand topical pre- or post-exposure HIV prevention.
ABSTRACT
Vaginal inserts that can be used on demand before or after sex may be a desirable human immunodeficiency virus (HIV) prevention option for women. We recently showed that inserts containing tenofovir alafenamide fumarate (TAF, 20â mg) and elvitegravir (EVG, 16â mg) were highly protective against repeated simian/human immunodeficiency virus (SHIV) vaginal exposures when administered to macaques 4 hours before or after virus exposure (93% and 100%, respectively). Here, we show in the same macaque model that insert application 8 hours or 24 hours after exposure maintains high efficacy (94.4% and 77.2%, respectively). These data extend the protective window by TAF/EVG inserts and inform their clinical development for on-demand prophylaxis in women.
Subject(s)
Adenine , Alanine , Anti-HIV Agents , Quinolones , Simian Acquired Immunodeficiency Syndrome , Tenofovir , Animals , Tenofovir/administration & dosage , Tenofovir/analogs & derivatives , Female , Quinolones/administration & dosage , Quinolones/pharmacology , Alanine/administration & dosage , Simian Acquired Immunodeficiency Syndrome/prevention & control , Simian Acquired Immunodeficiency Syndrome/virology , Anti-HIV Agents/administration & dosage , Adenine/analogs & derivatives , Adenine/administration & dosage , Adenine/pharmacology , Adenine/therapeutic use , Vagina/virology , Vagina/drug effects , Simian Immunodeficiency Virus/drug effects , HIV Infections/prevention & control , HIV Infections/virology , Administration, Intravaginal , Macaca mulatta , Disease Models, AnimalABSTRACT
Our objective was to determine the effect of phosphodiesterase (PDE) inhibition on: 1) tyrosine phosphorylation of human spermatozoa at the tail level; and 2) sperm motion parameters and hyperactivated motility. The study was conducted with normozoospermic and asthenozoospermic samples incubated under in vitro capacitating conditions. The main outcome measures were computer-assisted sperm motion analysis and fluorescent immunodetection of phosphotyrosine-containing proteins. Pentoxifylline (PTX) was used as PDE inhibitor because of its wide use in the clinic. PTX-treatment significantly increased sperm velocity, hyperactivated motility and tyrosine-phosphorylation, both in normo and asthenozoospermic samples. Tyrosine-phosphorylation of tail proteins was highly conspicuous in both types of samples, showing no differential pattern after PTX-treatment. Normozoospermic samples treated with pentoxifylline showed an increase in the number of spermatozoa displaying hyperactivated movement and tyrosine-phosphorylation at the tail level. Preliminary data on asthenozoospermic samples exhibiting altered motion characteristics and defective phosphorylation of sperm-tail proteins showed that both defects can be concomitantly overcome by pentoxifylline treatment. Tyrosine-phosphorylation of sperm-tail proteins is underlying the enhancement of hyperactivated motility resulting from PDE inhibition by pentoxifylline.
Subject(s)
Humans , Male , Pentoxifylline/pharmacology , Phosphodiesterase Inhibitors/pharmacology , Sperm Motility/drug effects , Spermatozoa/metabolism , Tyrosine/metabolism , Fluorescent Antibody Technique, Indirect , Image Processing, Computer-Assisted , Phosphorylation/drug effects , Sperm Tail/drug effects , Spermatozoa/drug effects , Spermatozoa/pathologyABSTRACT
Our objective was to determine the effect of phosphodiesterase (PDE) inhibition on: 1) tyrosine phosphorylation of human spermatozoa at the tail level; and 2) sperm motion parameters and hyperactivated motility. The study was conducted with normozoospermic and asthenozoospermic samples incubated under in vitro capacitating conditions. The main outcome measures were computer-assisted sperm motion analysis and fluorescent immunodetection of phosphotyrosine-containing proteins. Pentoxifylline (PTX) was used as PDE inhibitor because of its wide use in the clinic. PTX-treatment significantly increased sperm velocity, hyperactivated motility and tyrosine-phosphorylation, both in normo and asthenozoospermic samples. Tyrosine-phosphorylation of tail proteins was highly conspicuous in both types of samples, showing no differential pattern after PTX-treatment. Normozoospermic samples treated with pentoxifylline showed an increase in the number of spermatozoa displaying hyperactivated movement and tyrosine-phosphorylation at the tail level. Preliminary data on asthenozoospermic samples exhibiting altered motion characteristics and defective phosphorylation of sperm-tail proteins showed that both defects can be concomitantly overcome by pentoxifylline treatment. Tyrosine-phosphorylation of sperm-tail proteins is underlying the enhancement of hyperactivated motility resulting from PDE inhibition by pentoxifylline.
ABSTRACT
Our objective was to study the incidence of sperm-tail phosphotyrosine immunoreactivity in normozoospermic and asthenozoospermic human sperm samples, its association with sperm motion parameters, particularly hyperactivated motility, and its potential involvement in the pathogenesis of asthenozoospermia. The work was conducted as a prospective experimental study in the Sperm Biology and Andrology laboratories of the Jones Institute, a medical school-based fertility center. The study subjects were healthy fertile male donors (normozoospermic samples) and infertile patients (asthenozoospermic samples) attending the center. Recently ejaculated semen samples were washed twice to eliminate seminal plasma and a swim-up was performed to select the motile population which, in turn, was incubated up to 18 h at 37 degrees C in 3.5
human serum albumin-supplemented Hams F10 to allow for capacitation. For evaluation, sperm aliquots were taken pre-swim-up (T0), immediately post swim-up (T1), at 6 h (T6), and 18 h (T18) of incubation. The main outcome measures were computer-analyzed sperm motion parameters and hyperactivated motility, and immunodetection of phosphotyrosine (PY)-containing proteins. During the capacitating incubation, normozoospermic samples displayed maximum motility, velocity, and hyperactivation at T6, significantly decreasing their values at T18. PY-proteins were located both at the tail and head of spermatozoa. Their expression increased progressively during the incubation, being present in about 70
of the sperm tails at T18. Asthenozoospermic samples showed an inability to respond to capacitation with an increase in motion parameters and PY-phosphorylation. At T6, both hyperactivation and PY-phosphorylation were significantly lower than in normal samples. Our results suggest that PY-phosphorylation of tail proteins is highly conspicuous in human spermatozoa, and increases its incidence in a time-dependent manner, as more sperm become capacitated. Asthenozoospermic samples displaying low percentages of motile sperm and altered motion characteristics showed a decreased incidence of PY-phosphorelated sperm. Tail protein PY-phosphorylation may be related to sperm movement, especially to hyperactivated motility and its deficiency may be associated to asthenozoospermia.
ABSTRACT
Introducción: Los primeros estudios relacionados con falla de fecundación en humanos se concentraron en la citogenética del oocito. Más recientemente, los avances en imágenes digitales y microscopía de fluorescencia han permitidos investigar eventos menos conocidos como la movilidad citoplásmica de los pronúcleos masculino y femenino y los mecanismos físicos que dirigen su unión. Objetivo: Analizar cualitativa y cuantitativamente oocitos no fecundados luego de FIV e ICSI, haciendo hincapié en la organización del citoesqueleto, estado de la cromatina, organización del áster y presencia de activaciones abortivas. Materiales y Métodos: Se estudiaron 248 oocitos clasificados como "no fecundados" luego de fertilización in vitro (FIV) e inyección intracitoplásmica de espermatozoides (ICSI) 20-40 hs post inseminación o inyección. El material se procesó para inmunofluorescencia mediante la utilización de anticuerpos monoclonales para la detección de Ó y ß tubulinas y Ó tubulinas acetiladas. El material genético se estudió por tinción con Hoechst 33258 y se analizó por microscopía óptica (UV). El análisis citogenético se realizó en 69 oocitos activados luego de ICSI de acuerdo a la técnica de Tarkowski (1966). Los resultados se analizaron estadísticamente mediante el test de Chi cuadrado. Resultados y Discusión: Inmunofluorescencia: 1) FIV: La principal causa de falla de fecundación luego de FIV fue la ausencia de penetración espermática (54,9 por ciento). De los restantes oocitos estudiados, el 11,4 por ciento mostraron una falla de activación oocitaria y el 23,9 por ciento presentaron fallas en los procesos de nucleación o migración de pronúcleos. 2) ICSI: La principal causa de falla de fecundación luego de ICSI resultó ser la falla de activación oocitaria (36,5 por ciento). Un 14,6 por ciento de los oocitos remanentes detuvieron su desarrollo en la primera placa metafásica. En general, las fallas detectadas luego de FIV ó ICSI resultaron cuantitativamente diferentes. Análisis cromosómico en oocitos activados post ICSI: El estudio cromosómico permitió identificar la presencia de activaciones abortivas, incluyendo metafases III (MIII), núcleos reticulares (NR) y núcleos telofásicos (NT)
Subject(s)
Humans , Female , Pregnancy , Abortion, Eugenic/trends , Fertilization in Vitro , Oocytes/transplantation , Biological Reactions , Fertilization/physiology , Sperm-Ovum Interactions/physiology , Oocytes/pathology , Biological Clocks/physiologyABSTRACT
Introducción: Los primeros estudios relacionados con falla de fecundación en humanos se concentraron en la citogenética del oocito. Más recientemente, los avances en imágenes digitales y microscopía de fluorescencia han permitidos investigar eventos menos conocidos como la movilidad citoplásmica de los pronúcleos masculino y femenino y los mecanismos físicos que dirigen su unión. Objetivo: Analizar cualitativa y cuantitativamente oocitos no fecundados luego de FIV e ICSI, haciendo hincapié en la organización del citoesqueleto, estado de la cromatina, organización del áster y presencia de activaciones abortivas. Materiales y Métodos: Se estudiaron 248 oocitos clasificados como "no fecundados" luego de fertilización in vitro (FIV) e inyección intracitoplásmica de espermatozoides (ICSI) 20-40 hs post inseminación o inyección. El material se procesó para inmunofluorescencia mediante la utilización de anticuerpos monoclonales para la detección de O y ß tubulinas y O tubulinas acetiladas. El material genético se estudió por tinción con Hoechst 33258 y se analizó por microscopía óptica (UV). El análisis citogenético se realizó en 69 oocitos activados luego de ICSI de acuerdo a la técnica de Tarkowski (1966). Los resultados se analizaron estadísticamente mediante el test de Chi cuadrado. Resultados y Discusión: Inmunofluorescencia: 1) FIV: La principal causa de falla de fecundación luego de FIV fue la ausencia de penetración espermática (54,9 por ciento). De los restantes oocitos estudiados, el 11,4 por ciento mostraron una falla de activación oocitaria y el 23,9 por ciento presentaron fallas en los procesos de nucleación o migración de pronúcleos. 2) ICSI: La principal causa de falla de fecundación luego de ICSI resultó ser la falla de activación oocitaria (36,5 por ciento). Un 14,6 por ciento de los oocitos remanentes detuvieron su desarrollo en la primera placa metafásica. En general, las fallas detectadas luego de FIV ó ICSI resultaron cuantitativamente diferentes. Análisis cromosómico en oocitos activados post ICSI: El estudio cromosómico permitió identificar la presencia de activaciones abortivas, incluyendo metafases III (MIII), núcleos reticulares (NR) y núcleos telofásicos (NT) (AU)